Yasir S. Kheir

Clinical Response and Safety of Letrozole-based Therapy in Postmenopausal Sudanese Women with Estrogen Receptor-positive/HER2-Negative Breast Cancer: A Retrospective Cohort Study

Lina Hassan Elobied, Abdulbagi Elbadri Ali, Mohamed Thabit Ahmed, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2026

Introduction: Estrogen receptor-positive/HER2-negative breast cancer is the most common molecular subtype of breast cancer. Aromatase inhibitors such as letrozole are part of the standard endocrine treatment regimen for postmenopausal patients; however, real-world evidence on pat...

Open access Research Article 10.9734/jamps/2026/v28i8883

Early Haematological Response and Short-Term Safety of Frontline Imatinib in Adults with Chronic Myeloid Leukaemia: A Retrospective Study in a Resource-Limited Setting

Sara S. Abdelrahim, Mohammed H. Alnazeer, Mawahib A. Mustafa, Safa A. Abdalla, Elkhanssa Abdelhameed Ahmed Elhag, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2026

Background: Imatinib mesylate is a tyrosine kinase inhibitor that has transformed the treatment of chronic myeloid leukaemia. However, information on its real-world use among sub-Saharan African populations remains limited. Aims: This study evaluated early haematological response...

Open access Research Article 10.9734/jamps/2026/v28i8879